Clovis Oncology Inc (CLVS)

54.76
0.70 1.30
NASDAQ : Health Care
Prev Close 55.46
Open 54.00
Day Low/High 52.95 / 54.78
52 Wk Low/High 11.57 / 116.75
Volume 910.88K
Avg Volume 2.15M
Exchange NASDAQ
Shares Outstanding 44.34M
Market Cap 2.46B
EPS -9.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Clovis Oncology Announces Exercise In Full Of Underwriters' Option To Purchase Additional Shares Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the underwriters of its recently announced public offering of its common stock have exercised in full their option to purchase an additional 750,000 shares.

Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock

Clovis Oncology Announces Upsizing And Pricing Of Public Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an underwritten public offering of 5,000,000 shares of its common stock at $41.

Clovis Oncology Announces Proposed Offering Of Common Stock

Clovis Oncology Announces Proposed Offering Of Common Stock

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has commenced an underwritten public offering of shares of its common stock to raise aggregate proceeds of approximately $175 million.

17 Thoughts on Biotech Stocks to Kick Off 2017

17 Thoughts on Biotech Stocks to Kick Off 2017

Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.

Noteworthy Monday Option Activity: CLVS, GTY, BEAT

Noteworthy Monday Option Activity: CLVS, GTY, BEAT

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Clovis Oncology Inc , where a total of 10,313 contracts have traded so far, representing approximately 1.0 million underlying shares. That amounts to about 75.4% of CLVS's average daily trading volume over the past month of 1.4 million shares.

Big-Cap Tech Names, Biotechs, Oils Lifting Market

Big-Cap Tech Names, Biotechs, Oils Lifting Market

The number of new 12-month highs has climbed to 240.

Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug

Clovis Oncology Gets FDA Approval for New Ovarian Cancer Drug

A new treatment has been approved by the FDA for treatment of ovarian cancer. The treatment is made by Clovis Oncology.

Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug

Clovis Oncology Secures FDA Approval for New Ovarian Cancer Drug

Clovis will market the new drug under the brand name Rubraca.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Clovis Oncology Inc.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Clovis Oncology Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Clovis Oncology Inc.

First Week of July 2017 Options Trading For Clovis Oncology (CLVS)

First Week of July 2017 Options Trading For Clovis Oncology (CLVS)

Investors in Clovis Oncology Inc saw new options become available this week, for the July 2017 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According To A Recently Filed Lawsuit

Robbins Arroyo LLP: Clovis Oncology, Inc. (CLVS) Misled Shareholders According To A Recently Filed Lawsuit

Shareholder rights law firm Robbins Arroyo LLP announces that a lawsuit was filed against Clovis Oncology, Inc.

CLVS Crosses Above Average Analyst Target

CLVS Crosses Above Average Analyst Target

In recent trading, shares of Clovis Oncology Inc have crossed above the average analyst 12-month target price of $33.14, changing hands for $33.98/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level.

Clovis Oncology Announces Q3 2016 Operating Results And Corporate Update

Clovis Oncology Announces Q3 2016 Operating Results And Corporate Update

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2016, and provided an update on the Company's clinical development programs and regulatory outlook for the remainder...

'Mad Money' Lightning Round: No Sunshine for Solar Plays

'Mad Money' Lightning Round: No Sunshine for Solar Plays

But, Jim Cramer says, he thinks Elon Musk's solar shingles look really nice.

Jim Cramer's 'Mad Money' Recap: Earnings, Politics and Uncertainty Stir the Pot

Jim Cramer's 'Mad Money' Recap: Earnings, Politics and Uncertainty Stir the Pot

Investors need to sift through the confusing crosswinds hitting the market, Jim Cramer says.

Clovis Oncology To Present At The 2016 Credit Suisse Healthcare Conference

Clovis Oncology To Present At The 2016 Credit Suisse Healthcare Conference

Clovis Oncology, Inc. (Nasdaq: CLVS) today announced that Patrick Mahaffy, the Company's President and CEO, will present at the 2016 Credit Suisse Healthcare Conference on Tuesday, November 8, at 1:00pm MST.

Clovis Oncology To Announce Third Quarter 2016 Financial Results And Host Webcast Conference Call On November 3

Clovis Oncology To Announce Third Quarter 2016 Financial Results And Host Webcast Conference Call On November 3

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2016 financial results on Thursday, November 3, 2016, after the close of the U.

After FDA Approval, Merck Posts Better-Than-Expected Earnings

After FDA Approval, Merck Posts Better-Than-Expected Earnings

A day after winning approval for a cancer drug, Merck posts earnings and sales that beat consensus estimates.

'Mad Money' Lightning Round: People Keep Underrating Cable Stocks

'Mad Money' Lightning Round: People Keep Underrating Cable Stocks

Jim Cramer says he doesn't like solar companies, but ICE is cool. Cable stocks, he says, are underrated.

Jim Cramer's 'Mad Money' Recap: These Companies Have Changed How We Live

Jim Cramer's 'Mad Money' Recap: These Companies Have Changed How We Live

Staying home is the new going out, and these companies are profiting, Cramer says.

How to Anticipate When a Positive Stock Trend Is About to Reverse

How to Anticipate When a Positive Stock Trend Is About to Reverse

Many traders follow trends, but these can change quickly, sending a stock plummeting. There are signals that will help a trader know how to avoid this type of pattern.

Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows

Tesaro Drug Delays Recurrence of Ovarian Cancer, New Clinical Trial Shows

Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.

Clovis Oncology (CLVS) Stock Tumbles on Trial Update, SunTrust Bullish

Clovis Oncology (CLVS) Stock Tumbles on Trial Update, SunTrust Bullish

Clovis Oncology (CLVS) gave an update on a clinical trial for its rucaparib drug on Friday, showing its candidate might be inferior to competitors.

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition

Takeover speculation that had fueled the recent rise in Clovis' stock price looks to be subsiding.

Clovis Oncology Presents Efficacy And Safety Data From New Drug Application (NDA) Population For Rucaparib In The Treatment Of Advanced Mutant BRCA Ovarian Cancer At 2016 ESMO Congress

Clovis Oncology Presents Efficacy And Safety Data From New Drug Application (NDA) Population For Rucaparib In The Treatment Of Advanced Mutant BRCA Ovarian Cancer At 2016 ESMO Congress

Clovis Oncology (NASDAQ:CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.